MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance

Justin Y. Jeon, Richard L. Bradley, Efi G. Kokkotou, Francis E. Marino, Xiaomei Wang, Pavlos Pissios, Eleftheria Maratos-Flier

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Ablation of the hypothalamic peptide, melanin-concentrating hormone (MCH), leads to a lean phenotype and resistance to diet-induced obesity. Observation of MCH-/- mice at older ages suggested that these effects persist in mice >1 year old. Leanness secondary to caloric restriction is known to be associated with improved glucose tolerance as well as an overall increase in life span. Because the MCH-/- model represents leanness secondary to increased energy expenditure rather than caloric restriction, we were interested in determining whether this model of leanness would be associated with beneficial metabolic effects at older ages. To assess the effects of MCH ablation over a more prolonged period, we monitored male and female MCH -/- mice up to 19 months. The lean phenotype of MCH-/- mice persisted over the duration of the study. At 19 months, MCH-/- male and female mice weighed 23.4 and 30.8% less than their wild-type counterparts, a result of reduced fat mass in MCH-/- mice. Aged MCH-/- mice exhibited better glucose tolerance and were more insulin sensitive compared with wild-type controls. Aging-associated decreases in locomotor activity were also attenuated in MCH-/- mice. We also evaluated two molecules implicated in the pathophysiology of aging, p53 and silent inflammatory regulator 2 (Sir2). We found that expression of the tumor suppressor protein p53 was higher in MCH-/- mice at 9 and 19 months of age. In contrast, expression of Sir2 was unchanged. In aggregate, these findings suggest that MCH ablation improves the long-term outcome for several indicators of the aging process.

Original languageEnglish
Pages (from-to)428-434
Number of pages7
JournalDiabetes
Volume55
Issue number2
DOIs
Publication statusPublished - 2006 Feb 1

Fingerprint

Insulin Resistance
Body Weight
Thinness
Caloric Restriction
melanin-concentrating hormone
Phenotype
Tumor Suppressor Protein p53
Glucose
Locomotion
Energy Metabolism
Obesity
Fats
Observation
Insulin
Diet
Peptides

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Jeon, J. Y., Bradley, R. L., Kokkotou, E. G., Marino, F. E., Wang, X., Pissios, P., & Maratos-Flier, E. (2006). MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance. Diabetes, 55(2), 428-434. https://doi.org/10.2337/diabetes.55.02.06.db05-0203
Jeon, Justin Y. ; Bradley, Richard L. ; Kokkotou, Efi G. ; Marino, Francis E. ; Wang, Xiaomei ; Pissios, Pavlos ; Maratos-Flier, Eleftheria. / MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance. In: Diabetes. 2006 ; Vol. 55, No. 2. pp. 428-434.
@article{92cc563a81d54f938ea10f507dc99a4a,
title = "MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance",
abstract = "Ablation of the hypothalamic peptide, melanin-concentrating hormone (MCH), leads to a lean phenotype and resistance to diet-induced obesity. Observation of MCH-/- mice at older ages suggested that these effects persist in mice >1 year old. Leanness secondary to caloric restriction is known to be associated with improved glucose tolerance as well as an overall increase in life span. Because the MCH-/- model represents leanness secondary to increased energy expenditure rather than caloric restriction, we were interested in determining whether this model of leanness would be associated with beneficial metabolic effects at older ages. To assess the effects of MCH ablation over a more prolonged period, we monitored male and female MCH -/- mice up to 19 months. The lean phenotype of MCH-/- mice persisted over the duration of the study. At 19 months, MCH-/- male and female mice weighed 23.4 and 30.8{\%} less than their wild-type counterparts, a result of reduced fat mass in MCH-/- mice. Aged MCH-/- mice exhibited better glucose tolerance and were more insulin sensitive compared with wild-type controls. Aging-associated decreases in locomotor activity were also attenuated in MCH-/- mice. We also evaluated two molecules implicated in the pathophysiology of aging, p53 and silent inflammatory regulator 2 (Sir2). We found that expression of the tumor suppressor protein p53 was higher in MCH-/- mice at 9 and 19 months of age. In contrast, expression of Sir2 was unchanged. In aggregate, these findings suggest that MCH ablation improves the long-term outcome for several indicators of the aging process.",
author = "Jeon, {Justin Y.} and Bradley, {Richard L.} and Kokkotou, {Efi G.} and Marino, {Francis E.} and Xiaomei Wang and Pavlos Pissios and Eleftheria Maratos-Flier",
year = "2006",
month = "2",
day = "1",
doi = "10.2337/diabetes.55.02.06.db05-0203",
language = "English",
volume = "55",
pages = "428--434",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "2",

}

Jeon, JY, Bradley, RL, Kokkotou, EG, Marino, FE, Wang, X, Pissios, P & Maratos-Flier, E 2006, 'MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance', Diabetes, vol. 55, no. 2, pp. 428-434. https://doi.org/10.2337/diabetes.55.02.06.db05-0203

MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance. / Jeon, Justin Y.; Bradley, Richard L.; Kokkotou, Efi G.; Marino, Francis E.; Wang, Xiaomei; Pissios, Pavlos; Maratos-Flier, Eleftheria.

In: Diabetes, Vol. 55, No. 2, 01.02.2006, p. 428-434.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance

AU - Jeon, Justin Y.

AU - Bradley, Richard L.

AU - Kokkotou, Efi G.

AU - Marino, Francis E.

AU - Wang, Xiaomei

AU - Pissios, Pavlos

AU - Maratos-Flier, Eleftheria

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Ablation of the hypothalamic peptide, melanin-concentrating hormone (MCH), leads to a lean phenotype and resistance to diet-induced obesity. Observation of MCH-/- mice at older ages suggested that these effects persist in mice >1 year old. Leanness secondary to caloric restriction is known to be associated with improved glucose tolerance as well as an overall increase in life span. Because the MCH-/- model represents leanness secondary to increased energy expenditure rather than caloric restriction, we were interested in determining whether this model of leanness would be associated with beneficial metabolic effects at older ages. To assess the effects of MCH ablation over a more prolonged period, we monitored male and female MCH -/- mice up to 19 months. The lean phenotype of MCH-/- mice persisted over the duration of the study. At 19 months, MCH-/- male and female mice weighed 23.4 and 30.8% less than their wild-type counterparts, a result of reduced fat mass in MCH-/- mice. Aged MCH-/- mice exhibited better glucose tolerance and were more insulin sensitive compared with wild-type controls. Aging-associated decreases in locomotor activity were also attenuated in MCH-/- mice. We also evaluated two molecules implicated in the pathophysiology of aging, p53 and silent inflammatory regulator 2 (Sir2). We found that expression of the tumor suppressor protein p53 was higher in MCH-/- mice at 9 and 19 months of age. In contrast, expression of Sir2 was unchanged. In aggregate, these findings suggest that MCH ablation improves the long-term outcome for several indicators of the aging process.

AB - Ablation of the hypothalamic peptide, melanin-concentrating hormone (MCH), leads to a lean phenotype and resistance to diet-induced obesity. Observation of MCH-/- mice at older ages suggested that these effects persist in mice >1 year old. Leanness secondary to caloric restriction is known to be associated with improved glucose tolerance as well as an overall increase in life span. Because the MCH-/- model represents leanness secondary to increased energy expenditure rather than caloric restriction, we were interested in determining whether this model of leanness would be associated with beneficial metabolic effects at older ages. To assess the effects of MCH ablation over a more prolonged period, we monitored male and female MCH -/- mice up to 19 months. The lean phenotype of MCH-/- mice persisted over the duration of the study. At 19 months, MCH-/- male and female mice weighed 23.4 and 30.8% less than their wild-type counterparts, a result of reduced fat mass in MCH-/- mice. Aged MCH-/- mice exhibited better glucose tolerance and were more insulin sensitive compared with wild-type controls. Aging-associated decreases in locomotor activity were also attenuated in MCH-/- mice. We also evaluated two molecules implicated in the pathophysiology of aging, p53 and silent inflammatory regulator 2 (Sir2). We found that expression of the tumor suppressor protein p53 was higher in MCH-/- mice at 9 and 19 months of age. In contrast, expression of Sir2 was unchanged. In aggregate, these findings suggest that MCH ablation improves the long-term outcome for several indicators of the aging process.

UR - http://www.scopus.com/inward/record.url?scp=33644778822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644778822&partnerID=8YFLogxK

U2 - 10.2337/diabetes.55.02.06.db05-0203

DO - 10.2337/diabetes.55.02.06.db05-0203

M3 - Article

C2 - 16443777

AN - SCOPUS:33644778822

VL - 55

SP - 428

EP - 434

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -